Dermatology-focused pharmaceutical company; specific pipeline and commercial products not confidently known from public knowledge.
Dermatology-focused pharmaceutical company; specific pipeline and commercial products not confidently known from public knowledge.
Moat: none
Employees: 21
Size Veradermics (MANE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $5.27B, the 1140th largest of 3,085 United States companies the cockpit tracks. Shares closed at $124.86 on 18 Nov 2026.
Performance Over six months the shares gained 18.6%, against +2.9% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Short interest Short interest is 8.1% of the free float (30 Oct 2026).
Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — |
| Gross profit | $0 | $0 | $0 | $0 |
| EBITDA | n/a | -$72.3M | -$26.8M | -$17.3M |
| Net income | -$93.6M | -$70.0M | -$26.5M | -$16.5M |
| Free cash flow | n/a | -$71.6M | -$23.7M | -$13.5M |
| Capital expenditure | n/a | $24,000 | $0 | $0 |
| Total debt | $371,000 | $4,000 | $0 | $786,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Veradermics MANE | $5.27B | +19% | n/a | n/a | n/a | n/a |
| Hims & Hers Health HIMS | $4.00B | -26% | +30% | -1% | 1.7× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MANE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.8% | -2.1% | 11th highest of 21 |
| 6-month return | +18.6% | +2.9% | 5th highest of 21 |
| Distance from 52-week high | -20.3% | -31.1% | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 4.8× | 0.1% | +519.6% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 1.9× | 1.7% | -2.6% |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 7.8× | 5.0% | +192.5% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 6.8× | -4.4% | +93.6% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 3.1× | 6.6% | +35.4% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 4.6× | 16.5% | +12.2% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 7.6× | n/a | n/a |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 2.2× | 1.7% | +6.2% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 1.6× | -8.8% | +3.0% |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 7.1× | 20.2% | +13.3% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 7.6× | 17.3% | +19.9% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 10.2× | 26.4% | +5.5% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 7.3× | 8.0% | +10.0% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 4.5× | 15.9% | +12.7% |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 26.3× | 57.7% | +7.5% |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 4.5× | 6.2% | +13.9% |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | 9.6× | n/a | n/a |
| RemeGen 9995.HK | Hong Kong | $6.07B | -28% | +293% | 61% | 4.4× | -6.8% | +57.9% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | 5.0× | n/a | n/a |